Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAF V600E -Mutated Metastatic Lung Cancer.
Simple Summary: Patients with BRAFV600E-mutated metastatic lung cancer benefit from first-line BRAF plus MEK inhibitors and immune checkpoint inhibitor–chemotherapy. Nevertheless, a cost-effectiveness analysis comparing both treatments is lacking. This study suggests that despite the longer survival...
| Publicado en: | Current Oncology Vol. 33; no. 7; pp. 384 - 395 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195807416&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195807416 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Jul2026 vid: 33 iid: 7 pid: 97109 pub: MDPI artinfo: ui: 195807416 10.3390/curroncol33070384 195807416 ppf: 384 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Cost-Effectiveness of First-Line Immunochemotherapy Versus BRAF Plus MEK Inhibitors in BRAF V600E -Mutated Metastatic Lung Cancer. aug: au: Chen, Chian-Wei Tsai, Jui-Hung Tsai, Sheng-Han Chen, Li-Jun Yang, Szu-Chun affil: Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan sug: ab: Simple Summary: Patients with BRAFV600E-mutated metastatic lung cancer benefit from first-line BRAF plus MEK inhibitors and immune checkpoint inhibitor–chemotherapy. Nevertheless, a cost-effectiveness analysis comparing both treatments is lacking. This study suggests that despite the longer survival of first-line immune checkpoint inhibitor–chemotherapy compared with BRAF plus MEK inhibitors, the incremental cost-effectiveness ratios (Taiwan: $73,561/QALY; US: $290,279/QALY) exceeded the respective willingness-to-pay thresholds. Namely, first-line immune checkpoint inhibitor–chemotherapy is not a cost-effective strategy for patients with BRAFV600E-mutated metastatic lung cancer. Patients with BRAFV600E-mutated metastatic lung cancer benefit from both BRAF plus MEK inhibitors and immune checkpoint inhibitor (ICI)–chemotherapy. This study evaluated the cost-effectiveness of first-line ICI–chemotherapy compared with BRAF plus MEK inhibitors in these patients. This economic analysis, with a 15-year time horizon and an annual 3% discount, was conducted from the perspective of the healthcare sectors in Taiwan and the US. Simulated patients were entered into partitioned survival models upon initiation of first-line therapies. The model inputs were derived from the FRONT-BRAF study (progression-free/overall survival, adverse events, and subsequent therapies), insurance payments or retail prices (costs of drugs, physician visits, monitoring, adverse events, and end-of-life care), and a hospital cohort (health utility). Deterministic and probabilistic analyses were performed. The incremental cost-effectiveness ratios (ICERs) of ICI–chemotherapy compared with BRAF plus MEK inhibitors (Taiwan: $73,561/QALY; US: $290,279/QALY) exceeded the willingness-to-pay (WTP) thresholds (Taiwan: $70,000/QALY; US: $150,000/QALY). The drug costs of subsequent therapies and the utility values of the progressive-disease state were the major determinants of ICERs. In Taiwan, ICI–chemotherapy had a 41.0% probability of being cost-effective at the WTP threshold. ICI–chemotherapy had a higher probability of being cost-effective than BRAF plus MEK inhibitors when the WTP exceeded $300,000/QALY in the US. Our analysis suggests that, despite the longer survival of first-line ICI–chemotherapy compared with BRAF plus MEK inhibitors, ICI–chemotherapy is not a cost-effective strategy for patients with BRAFV600E-mutated metastatic lung cancer. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|